This review focuses on the mechanisms of action of histone deacetylase (HDAC) inhibitors
(HDACi), a group of recently discovered 'targeted'anticancer agents. There are 18 HDACs …

Histone deacetylase (HDAC), inhibitors represent a new class of targeted anti‐cancer
agents. Several of these compounds are in clinical trials with significant activity against a …

The role of histone deacetylases (HDAC) and the potential of these enzymes as therapeutic
targets for cancer, neurodegenerative diseases and a number of other disorders is an area …

Histone deacetylases (HDACs) have recently emerged as an important target for therapeutic
intervention in cancer and potentially other human diseases. By modulating the acetylation …

Histone deacetylases (HDACs) and histone acetyltransferases are enzymes that regulate
chromatin structure and function through the removal and addition, respectively, of the acetyl …

Epigenic modifications, mainly DNA methylation and acetylation, are recognized as the main
mechanisms contributing to the malignant phenotype. Acetylation and deacetylation are …

Histone deacetylases (HDACs) remove the acetyl groups of lysine residues of histone tails
leading to chromatin compaction and transcriptional repression. In addition, HDACs can …

Aberrant gene regulation plays an important role in tumor initiation and progression, and the
acetylation of histones is a well understood key component of gene regulation. Histone …

Histone deacetylase inhibitors (HDACi) are a promising new class of chemotherapeutic drug
currently in early phase clinical trials. A large number of structurally diverse HDACi have …

The histone deacetylase inhibitors (HDACi) have demonstrated anticancer efficacy across a
range of malignancies, most impressively in the hematological cancers. It is uncertain …